Effect of deep tissue laser therapy treatment on peripheral neuropathic pain in older adults with type 2 diabetes: a pilot randomized clinical trial

Table 6 Statistical analysis

Outcome	Test	Group	ANOVA Pre-test-Post-test Main Effect	ANOVA Interaction p-value	Pre-test vs Post-test
Quality of Life	SF-36	DTLT	< .001	< .001 ^a	< 0.001
Quality of Life	SF-36	SLT	< .001	< .001 ^a	= 0.194
Pain	PDQ	DTLT	< .05	< .01 ^a	< 0.001
	PDQ	SLT	< .05	< .01 ^a	< 0.01
	QVAS	DTLT	< .001	< .01 ^a	< 0.001
	QVAS	SLT	< .001	< .01 ^a	= 0.003
	NPS	DTLT	< .001	< .01 ^a	< 0.001
	NPS	SLT	< .001	< .01 ^a	= 0.019
Functionality	TUG	DTLT	< .001	> .05 ^b
Functionality	TUG	SLT	< .001	> .05 ^b
Systemic Inflammation	IL-6	DTLT	< .05	> .05 ^b
	IL-6	SLT	< .05	> .05 ^b
	MCP-1	DTLT	> .05	> .05 ^b
	MCP-1	SLT	> .05	> .05 ^b
	RANTES	DTLT	> .05	> .05 ^b
	RANTES	SLT	> .05	> .05 ^b
	TNF-α	DTLT	> .05	> .05 ^b
	TNF-α	SLT	> .05	> .05 ^b

^a For these comparisons, the ANOVA interaction was significant, and unpaired t-tests were used to further explore the differences in change between the groups. The t-tests showed that there were significant differences in the pre-test-post-test mean change of the SF-36, PDQ, QVAS and NPS metrics; in each case, the change was greatest for the DTLT group – taken to be indicative of treatment effect
^b For these comparisons, the ANOVA interaction was not significant. The pre-test vs post-test comparison in the ANOVA suggested that the mean values of the TUG test and IL-6 serum concentration decreased from pre-test to post-test and that there were no significant pre-test-post-test changes in the mean values of MCP-1, RANTES, and TNF-α

ISSN: 1471-2318